You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 7, 2025

CLINICAL TRIALS PROFILE FOR FOLVITE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for FOLVITE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02318446 ↗ Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics Unknown status Maharashtra University of Health Sciences Phase 3 2015-03-01 The present study is planned to study effect of folic acid supplementation on homocysteine levels and CV risk factors such as BP and lipids in adolescent epileptics taking anti-epileptic drugs (AEDs).
NCT02930343 ↗ Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy Terminated Jawaharlal Institute of Postgraduate Medical Education & Research Phase 3 2016-09-01 RA (Rheuatoid arthritis) is a multisystem disease that mainly involves joints resulting in destructive arthritis if not treated rapidly. Inspite of various advances in field of early diagnosis and treatment of RA, there is still a need for better understanding of the efficacy and safety of various combinations of conventional DMARDS, and to rank them in order accordingly, so as to give a clearer vision for further management of RA once MTX monotherapy fails, so as to achieve remission as soon as possible. The study will be conducted at the Department of Clinical Immunology, JIPMER (Jawaharlal Institute of Postgraduate Medical Education & Research). patients who fail methotrexate monotherapy will be randomised to 2 treatment arms - either a combination of Sulfasalazine (SSZ), Hydroxychloroquine (HCQ) and Methotrexate (MTX) or Leflunomide (LEF), Hydroxychloroquine (HCQ) and Methotrexate (MTX)
NCT03193788 ↗ Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Unknown status Korean Cancer Study Group Phase 3 2017-01-01 This study aims to verify superiority of pemetrexed maintenance to observation for patient without disease progression after 1 st line cisplatin-based chemotherapy.
NCT03193788 ↗ Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Unknown status Asan Medical Center Phase 3 2017-01-01 This study aims to verify superiority of pemetrexed maintenance to observation for patient without disease progression after 1 st line cisplatin-based chemotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for FOLVITE

Condition Name

Condition Name for FOLVITE
Intervention Trials
Bladder Cancer 1
Epilepsy 1
Rheumatoid Arthritis 1
Transitional Cell Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for FOLVITE
Intervention Trials
Arthritis 1
Epilepsy 1
Urinary Bladder Neoplasms 1
Ureteral Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for FOLVITE

Trials by Country

Trials by Country for FOLVITE
Location Trials
India 2
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for FOLVITE

Clinical Trial Phase

Clinical Trial Phase for FOLVITE
Clinical Trial Phase Trials
Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for FOLVITE
Clinical Trial Phase Trials
Unknown status 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for FOLVITE

Sponsor Name

Sponsor Name for FOLVITE
Sponsor Trials
Maharashtra University of Health Sciences 1
Jawaharlal Institute of Postgraduate Medical Education & Research 1
Korean Cancer Study Group 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for FOLVITE
Sponsor Trials
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

FOLVITE Market Analysis and Financial Projection

Folvite: Clinical Trials, Market Analysis, and Projections

Introduction to Folvite

Folvite, a synthetic form of folate (folic acid), is a crucial B vitamin used to treat or prevent low folate levels, which can lead to various types of anemia and other health issues. Here, we will delve into the clinical aspects, market analysis, and future projections of Folvite.

Clinical Uses and Dosage of Folvite

Folvite is effective in treating megaloblastic anemias caused by folic acid deficiency, often seen in conditions such as tropical or non-tropical sprue, nutritional anemias, pregnancy, infancy, and childhood. The dosage can vary depending on the severity of the condition and the patient's age.

  • Oral Administration: Folic acid is well absorbed orally, but in severe cases of intestinal malabsorption, intramuscular, intravenous, or subcutaneous routes may be used[1][4].
  • Therapeutic Dosage: Adults and children typically receive up to 1.0 mg daily, with resistant cases requiring larger doses. Maintenance levels range from 0.1 mg for infants to 0.8 mg for pregnant and lactating women[1].

Side Effects and Precautions

While generally well-tolerated, Folvite can cause some side effects and requires careful management.

  • Side Effects: Allergic sensitization, rash, itching, swelling, and in rare cases, serious allergic reactions can occur[1][4].
  • Precautions: Folic acid can obscure pernicious anemia if given in doses above 0.1 mg daily, as it can lead to hematologic remission while neurological manifestations progress[1].

Market Analysis of Folate

The global folate market, which includes Folvite, is experiencing significant growth driven by several factors.

Market Size and Growth

  • The global folate market was valued at USD 880 million in 2022 and is projected to reach over USD 1,598.33 million by 2032, growing at a CAGR of 6.20% from 2023 to 2032[2].
  • Another report estimates the market size to be USD 2.4 billion in 2023, expected to grow at a CAGR of 5.11% to nearly USD 3.40 billion by 2030[5].

Regional Insights

  • Asia Pacific: This region is expected to register the fastest growth rate, driven by increasing investments by key market players and growing adoption in medical industries. The region's market size surpassed USD 343.20 million in 2022 and is predicted to reach over USD 629.25 million by 2032[2].
  • North America: This region currently dominates the market due to high demand from pharmaceutical and nutraceutical industries, particularly in the U.S. and Canada[2].

Key Market Segments

  • Type: The market is segmented into 5-MTHF Calcium Salt and 5-MTHF Glucosamine Salt, with the 5-MTHF Calcium Salt segment projected to dominate due to its role in methylation, homocysteine conversion, and DNA synthesis[2][5].
  • Application: The market is segmented into food industry, nutraceuticals, agriculture, and pharmaceuticals. The food industry and pharmaceuticals & nutraceuticals segments are driving growth due to increasing demand for folate-based products[2][5].

Impact of COVID-19 on the Folate Market

The COVID-19 pandemic has significantly impacted the folate market.

  • Increased Demand: The pandemic led to an exponential rise in demand for vitamin supplements, including folate, as people sought to boost their immune systems and overall health[2].
  • Market Growth: This increased demand has created lucrative growth opportunities for folate market players, particularly in the food and pharmaceutical industries[2].

Technological Advancements and Bioavailability

Technological advancements are enhancing the stability and bioavailability of folate in fortified foods.

  • Microencapsulation: Techniques such as microencapsulation have improved folate stability in fortified foods, increasing its effectiveness[5].
  • New Formulations: Companies like DSM-Firmenich and BASF are developing new folate fortification and bioavailability technologies, including folic acid supplements aimed at improving prenatal health[5].

Key Players in the Folate Market

Several key players are driving the growth of the folate market.

  • DSM N.V.: Known for its innovative folate fortification technologies and prenatal health supplements[5].
  • BASF: Developing new formulations for fortified food products[5].
  • Other Players: Companies like Emcure Pharmaceuticals Ltd, Gemini Pharmaceuticals, Inc., and Zydus Pharmaceuticals USA are also significant contributors to the market[5].

Clinical Trials and Research

While Folvite itself is not typically the subject of new clinical trials due to its established use, ongoing research in related areas can impact its market.

  • General Trends: The increasing number of clinical trials globally, especially in areas like oncology, can drive demand for vitamins and supplements, including folate, as part of supportive care[3].

Key Takeaways

  • Clinical Use: Folvite is crucial for treating megaloblastic anemias and preventing folate deficiency.
  • Market Growth: The global folate market is expected to grow significantly, driven by increasing demand in pharmaceutical and nutraceutical industries.
  • Regional Focus: Asia Pacific and North America are key regions driving market growth.
  • Technological Advancements: Improvements in microencapsulation and new formulations are enhancing folate bioavailability.
  • Key Players: Companies like DSM N.V. and BASF are leading innovations in the folate market.

FAQs

What is Folvite used for?

Folvite is used to treat or prevent low folate levels, which can lead to megaloblastic anemias and other health issues.

What are the common side effects of Folvite?

Common side effects include allergic sensitization, rash, itching, and swelling. Rarely, serious allergic reactions can occur.

How is Folvite administered?

Folvite can be administered orally, but in severe cases, intramuscular, intravenous, or subcutaneous routes may be used.

What is the projected growth rate of the global folate market?

The global folate market is projected to grow at a CAGR of 6.20% from 2023 to 2032.

Which region is expected to dominate the folate market?

North America currently dominates the market, but the Asia Pacific region is expected to register the fastest growth rate.

What technological advancements are improving the folate market?

Techniques such as microencapsulation and new formulations by companies like DSM-Firmenich and BASF are enhancing folate stability and bioavailability.

Sources

  1. RxList: Folvite (Folic Acid): Side Effects, Uses, Dosage, Interactions, Warnings.
  2. Precedence Research: Folate Market Size to Hit US$ 1598.33 Million by 2032.
  3. GlobeNewswire: Clinical Trial Investigative Site Network Market Analysis Report 2025-2030.
  4. WebMD: Folvite Tablet - Uses, Side Effects, and More.
  5. Maximize Market Research: Folate Market - Industry Analysis and Forecast (2024-2030).

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.